

- Vici syndrome, 375e-1
 Vidarabine, 215e-3t, 215e-9, 417
 Video-assisted thoracic surgery, 1668–1669
 Video capsule endoscopy, 279
 Video game training, for cognitive training, 444e-11f, 444e-12
vif gene, 225e-3f, 1219f
 Vif protein, 225e-2
 Vigabatrin, 618
 Vilazodone, 2710t
 Vildagliptin, 2414t
 Villous adenoma, 254, 305
 Vimentin, 102e-11f, 372e-24t
 Vinblastine
 action of, 103e-14
 adverse effects of, 103e-12t
 alopecia, 380
 gonadal dysfunction, 103e-25
 myelotoxicity, 103e-14
 neurologic, 1793, 2686t
 phototoxicity, 389t
 Raynaud's phenomenon, 1649
 for bladder cancer, 577
 drug interactions of, 103e-12t
 for testicular cancer, 591
 Vinca alkaloids. *See also specific drugs*
 adverse effects of, 380, 622, 2686t
 for breast cancer, 531
 characteristics of, 103e-11–12t, 103e-14–15
 drug interactions of, 246e-3t
 Vincent's angina (trench mouth), 231, 233, 236, 238t, 1097
 Vincristine
 action of, 103e-14
 adverse effects of, 103e-11t, 103e-14
 depression, 63
 late, 620t
 nail disorders, 380
 neurologic, 607, 607t, 1793
 neuropathy, 103e-14, 622, 2686t
 for Ewing's sarcoma, 119e-4
 for gastric lymphoma, 536
 genetic variations in response to, 39t
 for gestational trophoblastic disease, 124e-5
 for lung cancer, 522
 for malignant pheochromocytoma, 2331
 for oligodendroglioma, 601
 for soft tissue sarcoma, 119e-2
 for thrombotic thrombocytopenic purpura, 730
 Vinorelbine
 action of, 103e-14
 adverse effects of, 103e-12t, 1798, 2686t
 for lung cancer, 518t, 520t, 522
 resistance to, 103e-14
 Vinyl chloride, 283, 477t, 2218t
 Violence
 assessment of, 2722–2723
 domestic. *See* Domestic abuse/violence
 VIP. *See* Vasoactive intestinal peptide (VIP)
 Vipers, 2734, 2737, 2738. *See also* Snakebites
 VIPoma (vasoactive intestinal peptidoma), 570
 clinical features of, 269, 305, 559t, 570, 2338
 diagnosis of, 570
 incidence of, 561
 locations of, 559t, 570
 in MEN 1, 2338
 treatment of, 570–571, 2338
 Viral encephalitis. *See* Encephalitis, viral
 Viral hemorrhagic fevers, 1320. *See also specific diseases*
 in bioterrorism, 261e-8
 clinical features of, 133t, 261e-5t, 261e-8, 782, 1320
 rash, 135
 diagnosis of, 261e-5t, 1320
 epidemiology of, 133t, 783
 etiology of, 782–783, 1320–1323
 pathogenesis of, 1320
 prevention of, 261e-5t, 261e-8
 treatment of, 215e-6, 261e-5t, 261e-8
 Viral hepatitis. *See* Hepatitis
 Viral infections. *See also specific diseases*
 arthropod-borne. *See* Arthropod-borne viruses
 cancer development and, 101e-7, 214e-7
 as cause of fever of unknown origin, 137t
 diagnosis of, 214e-8–9. *See also* Virus(es), laboratory identification of
 interferon production in, 214e-8
 persistent and latent, 214e-7
 in pregnancy, 50
 prevention of, 214e-9
 primary, 214e-6
 renal involvement in, 1849
 resistance to, 214e-8
 rodent-borne. *See* Rodent-borne viruses
 transmission of, 214e-6
 in transplant recipient
 after HSCT, 920t, 921–923, 921t
 after kidney transplantation, 924–926, 924t, 1829–1831, 1830t
 after liver transplantation, 924t, 927–928, 1341f, 2072–2073
 malignancies and, 928
 treatment of, 214e-9
 upper respiratory tract, 225–226
 Viral load, 150e-8
 Viral meningitis. *See* Meningitis, viral
 Viral orchitis, 2365
 Viral protein U (Vpu), 145e-9
 Viral (subacute) thyroiditis, 2298–2299, 2298f
 Virchow-Robin spaces, 906
 Virchow's node, 282, 286, 408, 555
 Viridans streptococci, 940t, 963, 964t, 971
 Virilization, 331
 Viroids, 214e-1
 Virtual bronchoscopy, 1666, 1666f
 Virtual colonoscopy, 540, 1898–1899, 1899f
 Virtue ethics, 17e-2
 Virulence, 145e-1
 Virus(es). *See also specific viruses*
 adherence of, 145e-1–2, 145e-2t
 bacterial hosts of, 86e-4
 cell entry by, 214e-1–2
 cell/tissue invasion by, 145e-7, 214e-13
 cytopathic effects and apoptosis inhibition, 214e-6
 definition of, 214e-1
 egress of, 214e-5
 gene expression and replication in, 214e-4–5
 growth after entry, 145e-4, 214e-5
 host range of, 214e-6
 host receptors of, 145e-3
 in human microbiome, 86e-4
 laboratory identification of
 ELISA, 214e-8
 genomics in, 769t, 772
 nucleic acid amplification, 214e-9
 specimen collection and transport, 150e-5t
 specimen-processing algorithm, 150e-6f
 tissue culture, 214e-9
 Western blot, 214e-8
 mutations of, 214e-5
 oncolytic, 91e-4
 protein activity in, 214e-5–6
 structure of, 214e-1, 214e-1f
 taxonomy of, 214e-1, 214e-2t, 214e-3f
 as therapeutic tool or agents, 91e-1t, 214e-9
 vaccines for, 214e-9
 virulence mechanisms of, 145e-9
 Virus-like particle(s), 86e-4
 Virus-like particle vaccines, 929
 Virusoids, 214e-1
 VISA (vancomycin-intermediate *S. aureus*), 933, 961
 Visceral afferent hypersensitivity, 261
 Visceral larva migrans. *See* Larva migrans, visceral
 Visceral leishmaniasis, 1387. *See also* Leishmania spp. infections
 clinical features of, 152e-3t, 1389, 1390f
 diagnosis of, 152e-3t, 245e-4t, 245e-6t, 1389, 1389f
 differential diagnosis of, 1390
 epidemiology of, 1387–1388, 1388t, 1389f
 in HIV infection, 798, 1268, 1389, 1391
 immunopathogenesis of, 1389
 incubation period for, 152e-3t
 prognosis of, 1391
 in returning war veterans, 152e-3t, 152e-8
 skin lesions after, 1391–1392, 1391t, 1392f
 treatment of, 152e-3t, 152e-7, 246e-10–11, 1390–1391
 Visceral pain, 60
 Vismodegib, 102e-5t, 103e-19t, 500, 500f
 Visual acuity, 149, 195, 196f, 2537
 Visual aura, 204
 Visual cortex, 176f
 Visual evoked potentials (VEPs), 442e-3
 Visual function, assessment of
 color vision, 197
 eye movements and alignment, 197
 pupils, 195–197, 196f
 refractive state, 195
 stereopsis, 197
 visual acuity, 195, 196f
 visual fields, 197–199, 198f, 2537
 Visual loss
 chemotherapy-induced, 607t
 chronic/permanent
 in cataract. *See* Cataract
 in central serous chorioretinopathy, 205
 in diabetic retinopathy. *See* Diabetic retinopathy
 in epiretinal membrane, 206
 in glaucoma. *See* Glaucoma
 in macular degeneration. *See* Macular degeneration
 in retinitis pigmentosa, 206, 206f, 431t
 trachoma and, 1172
 tumor-related, 206–207, 206f
 CMV retinitis and, 1192
 cortical, 199
 factitious, 204
 in giant cell arteritis, 108
 HSV keratitis and, 1178
 in legal blindness, 195
 in lepromatous leprosy, 1125
 with sellar masses, 2261
 transient or sudden, 200–202, 201f
 Visual object agnosia, 182
 Visual target cancellation test, 180
 Visual vertigo, 151
 Vital capacity, 306e-2, 306e-2f
 Vitamin(s), 96e-1. *See also specific vitamins*
 absorption of, 1933
 assessment of nutritional status, 462
 body stores of, 96e-1
 deficiencies of, 96e-1t, 2398
 functions of, 96e-2–3f
 genetic disorders related to, 435e-1t
 parenteral requirement for, 98e-5t
 recommended intake of, 95e-2t
 reference ranges for, 2766t
 in specialized nutritional support formulas, 98e-5
 structures of, 96e-2–3f
 Vitamin A, 96e-6
 deficiency of. *See* Vitamin A deficiency
 dietary sources of, 96e-6
 functions of, 96e-3f, 96e-6
 metabolism of, 96e-6
 parenteral requirement for, 98e-5t
 in pregnancy, 96e-7
 recommended intake of, 95e-2t
 reference range for, 2766t
 for retinitis pigmentosa, 206
 structure of, 96e-3f
 supplements. *See* Vitamin A supplements
 toxicity of, 96e-7, 463t, 2478
 Vitamin A deficiency
 clinical features of, 96e-1t, 96e-6, 463t
 esophageal cancer risk and, 533
 global considerations in, 96e-6, 461
 keratitis in, 199
 oral manifestations of, 236
 in pregnancy, 265e-12
 risk factors for, 96e-1t